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INTRODUCTION 
           Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease in 
which etiology is unknown. It is the commonest inflammatory arthritis affecting 
0.5 to 1 percent of general population all over the world. It is characterized by 
symmetric polyarthritis involving peripheral joints, resulting in joint destruction 
and disability. Although it is a disease of joints, abnormal immunological 
responses can lead to a variety of extra-articular manifestations including the 
involvement of blood vessels and heart.
1
 As compared to general population, 
people with rheumatoid arthritis experience disability, increased mortality and 
shortened life expectancy.
2
 
             Cardiovascular involvement is the leading cause of mortality in patients 
with Rheumatoid arthritis.
3
 This increased mortality due to cardiovascular 
involvement has been attributed to accelerated atherosclerosis which has been 
found to be independent of traditional risk factors for atherosclerosis.
4
 Accelerated 
atherosclerosis in Rheumatoid arthritis has been attributed to inflammation
5
, 
increased homocysteine levels
5
, imbalance in homeostasis
7,8
, immobility
9
, 
decreased antioxidants level
10
, side effects due to medications
11,12
, and abnormal 
lipid levels
13-16
. Among the above mentioned causes, inflammation has the 
strongest association for accelerated atherosclerosis in Rheumatoid arthritis 
patients. 
               In RA patients, indirect evidence of accelerated atherosclerosis comes 
from studies involving measurement of Carotid artery intima media thickness 
(CIMT) as a marker of atherosclerotic burden and cardiovascular risk
19,20
.  
Measurement of CIMT is an economical and noninvasive test which is quite 
reliable and sensitive for assessment of atherosclerosis
21
. Increased atherosclerosis 
in carotid arteries is indicative of atherosclerosis in multiple vascular beds 
including coronary arteries. So, measurement of CIMT is an important surrogate 
marker of increased cardiovascular risk including acute coronary syndrome
22
. 
Early diagnosis of atherosclerosis by measuring CIMT might trigger the preventive 
steps against atherosclerosis in RA patients thereby decreasing cardiovascular 
mortality. 
            In this background, a cross sectional study of CIMT in 40 cases of 
Rheumatoid arthritis patients of various age groups and duration of symptoms was 
conducted in south Indian patients, in southern districts of Tamilnadu, who were 
attending Government Rajaji Hospital, Madurai. The study was undertaken in the 
department of medicine, Government Rajaji Hospital, Madurai. 
            I hope this study may help to decrease cardiovascular mortality in 
Rheumatoid arthritis patients by early detection of accelerated atherosclerosis, 
there by instituting preventive treatment against atherosclerosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
             Rheumatoid arthritis (RA) is a symmetric chronic inflammatory 
polyarthritis that mainly affects the small joints of the hands and feet. 
HISTORICAL ASPECTS 
             First detailed case report of Rheumatoid arthritis was given by ‗Augustine 
Jacob Landre-Beauvais‘, a French medical student in 1850, who described acute 
onset of polyarthritis in a 35 year old female, which gradually ceased leaving 
behind deformities of hands and wrists, only to recur. 
             Garrod coined the term Rheumatoid arthritis in 1859. However the term 
came into use in 1941, prior to that it was known by many different terms such as 
proliferative arthritis, atrophic arthritis etc.. 
             Soranus, an Epherian, who lived in second century AD, wrote a treatise 
describing a polyarthritis associated with morning stiffness in which ―joints 
become twisted sideways or bent over backwards, or resting immovable upon their 
neighbours‖. 
             Two thousand years ago, Charaka in India described a chronic disease with 
joint swellings and subcutaneous nodules. The problem with accepting this or other 
earlier descriptions as first case reports is that, each of them had clear references to 
what might have been tophaceous gout. 
             In the translation from Latin by Short, of Syndenhams(1676), description 
of a polyarticular disease characterized by remissions and exacerbations, and his 
observation that ―the joints of his fingers had been as it were inverted and bulging 
out with the knots showing in their inner rather than the outer aspects of the 
fingers‖ the first description of  swan neck deformity was made. 
 
EPIDEMIOLOGY 
              Approximately 0.5 to 1 percent of adult population is affected by 
Rheumatoid arthritis worldwide. Prevalence of RA in India is 0.5 to 0.75 percent. 
It is more common in females than in males, the ratio being 2-3:1. There are 
evidences to suggest that the prevalence of RA has remained the same, but overall 
incidence is decreasing. This is because the individuals with RA are living longer. 
            Throughout the world there are some ethnic groups with high incidence of 
RA. The Native American Yakima, Pima, and Chippewa tribes of North America 
are examples of ethnic groups which have reported prevalence of nearly 7% in 
some studies. In contrast to this 0.2-0.4% is the reported prevalence rate in many 
population studies from Africa and Asia.  
ETIOLOGY 
             Etiology of Rheumatoid arthritis (RA) is unknown. Combined influence of 
genetic and environmental factors has been proposed to be responsible for 
manifestation of the disease. Either genetic or environmental factors are 
insufficient alone for the full expression of the disease.  
             Most compelling evidence for genetic component is the concordance rate 
of 12-15 percent for RA in monozygotic twins when one twin is affected, as 
compared to 1 percent for general population. There is also increased risk (about 2-
5 percent) in fraternal twin of a patient with RA. The risk in first degree relative is 
2-10 times greater than in general population. 
 Role of HLA-DR: 
           Class II MHC haplotype is one of the best studied genetic risk factors for 
RA.  About 40 percent of genetic influence in RA is accounted for  the structure of 
class II MHC molecules in antigen presenting cells. A genetic link of RA with 
HLA-DR was described in 1970s. The observation made was that in 70 percent of 
RA patients, genetic association with HLA-DR4 was present as in contrast to 
controls where only 30% association was there. It indicates that the relative risk of 
getting RA in individuals with HLA-DR4 is approximately 4 to 5. 
             Rheumatoid arthritis susceptibility is associated with the third hyper 
variable region of DRβ-chains from amino acids 70 through 74. The epitope is 
glutamine-leucine-alanine-alanine (QKRAA), which is a sequence seen in DR4 
and DR14, in addition to some DR1β-chains. 
           HLA-DR alleles observed to have association with Rheumatoid arthritis 
are
40
 
 HLA-DR1, 
  HLA-DR4Dw4,  
 HLA-DR4Dw14 
 HLA-DRw14Dw16 
There are many other additional genetic influences in RA as follows 
1. Many healthy individuals carry QKRAA motif and they do not 
develop RA. So, some other genes must also be involved for 
manifestation of RA. 
2. The converse hypothesis could also be possible, that is, appropriate T-
cell mediated response may be prevented because of limited binding 
of QKRAA to an arthrotropic agent. 
3. The association between the shared epitope and RA might have little 
to do with antigen recognition and might function by shaping the T 
cell repertoire in the thymus (or autoantibody production, as noted 
with anticitrullinated peptide antibodies). 
4. Specific DR sequences might alter intracellular MHC trafficking and 
antigen loading, indirectly affecting antigen presentation in a 
nonspecific fashion. 
5. There is some evidence that certain DR4 epitopes are protective, such 
as DERAA in the same region of the molecule. Various hypotheses 
have attempted to explain this observation, including the possibility 
that the protective epitope contributes to regulatory T cell function. 
Although more controversial, class II associations related to the DQ 
region of the class II MHC locus also have been described for RA. 
 
 
 
 
 
 
 
 Non–Class II Major Histocompatibility Complex Associations in Rheumatoid Arthritis 
Gene Region of Gene Studied 
Associated with Rheumatoid 
Arthritis
[∗] 
PTPN22 Coding + 
PADI4 Coding + 
STAT4 Intron + 
TRAF1-
C5 
Intron + 
TNF-α Promoter + 
IL-1 Coding region; association with IL-1β 
strongest 
+/- 
IL-1Ra Coding region + 
IL-3 Promoter + 
IL-4 IntronPromoter +- 
IL-6 Promoter - 
IL-10 Promoter - 
IL-12 3′ untranslated region - 
IFN-γ Intron microsatellite +/- 
CCR5 CCRδ32 allele + 
RANTES Promoter + 
MIF Promoter + 
RAGE Ligand-binding domain + 
CTLA4 3′ untranslated region + 
TGF-β Coding region + 
FcRγIII Coding region + 
CCR5, chemokine receptor 5; c-5, complement 5; FcRγIII, Fc receptor γIII; IFN-γ, interferon-γ; 
IL, interleukin; IL-1Ra, interleukin-1 receptor antagonist; MIF, macrophage inhibitory factor; 
RAGE, receptor for advanced glycosylation end products; RANTES, regulated on activation, 
normally T cell expressed and secreted; TGF-β, transforming growth factor-β; TNF-α, tumor 
necrosis factor-α; TRAF1, TNF-receptor associated factor 1. 
 
 
Gender: 
Rheumatoid arthritis is predominant in women. Female to male ratio is 2:1 to 3:1 
which is significant. This is attributed to the role of estrogens which are 
predominant sex hormones in females. The auto antibody producing B-cells 
exposed to estrogens are more resistant to apoptosis and hence the auto reactive B 
cell clones might escape tolerance. The effect of estrogens on T-lymophocytes is 
controversial, as estrogens tend to promote T-cell differentiation towards T-helper 
cells which produce anti –inflammatory cytokines like IL-4 and IL-13, which are 
present in only limited amounts in RA synovium. Estrogen receptors are expressed 
on fibroblast-like synoviocytes (FLS) and, when stimulated, increase production of 
metalloproteinases in the synovium. In macrophage cell lines, estrogen can 
enhance production of TNF-α. Taken together, these data suggest that the hormone 
milieu can have significant effects on the cells that are known to participate in RA. 
The effects are complex, however, and the specific mechanisms responsible for 
increased susceptibility of women to RA are uncertain. 
        Other endocrinal influences, including corticotropin releasing hormone or 
estrogen synthase, have been linked with Rheumatoid arthritis. Nulliparity also has 
been described as a risk factor, but not all studies confirm this. 
       During pregnancy, there can often be remission of the disease in the last 
trimester. In the first or second trimester, more than three quarters of pregnant 
patients with RA will improve, but 90 percent of these experience a flare of disease 
associated with an increase in RF titers in the weeks or months after child birth. 
The mechanism of protection is not defined, but might be due to the expression 
during pregnancy of suppressive cytokines such as IL-10, production of alpha 
fetoprotein, or alterations in cell mediated immunity. 
Tobacco: 
              Numerous environmental factors certainly contribute to RA susceptibility, 
although no specific exposure has been identified as a pivotal agent. Smoking is 
the best defined environmental risk factor for seropositive RA in certain 
populations. The reason for its influence on the development of synovitis is not 
fully defined, but could involve the activation of innate immunity and PADI in the 
airway. Citrullinated peptides have been detected in bronchoalveolar lavage 
samples of smokers, and this could provide a stimulus for generation of 
anticitrullinated peptide antibodies in susceptible individuals. Repeated activation 
of innate immunity, especially in an individual with underlying genetically 
determined autoreactivity, potentially could contribute to autoreactivity and the 
initiation of RA. 
          Although genetic factors predispose an individual to developing RA, the 
environment clearly also contributes. Many pathogens have been associated with 
RA, including viruses, retroviruses, and Mycoplasma, although a precise etiologic 
link has not been established. 
Possible Infectious Causes of RA: 
Infectious Agent Potential Pathogenic Mechanisms 
1. Mycoplasma Direct synovial infection; superantigens 
2. Parvovirus B19 Direct synovial infection 
3. Retroviruses Direct synovial infection 
4. Enteric bacteria Molecular mimicry (QKRAA) 
5. Mycobacterium Molecular mimicry (proteoglycans, QKRAA), 
immunostimulatory DNA 
6. Epstein-Barr virus Molecular mimicry (QKRAA) 
7. Bacterial cell walls Macrophage activation 
          Data suggest that a specific RA pathogen is unlikely. Repeated inflammatory 
insults, especially through specialized receptors that recognize common molecules 
produced by pathogens, in a genetically susceptible individual might contribute to 
breakdown of tolerance and subsequent autoimmunity. 
           Evidence of autoimmunity can be present in RA many years before the 
onset of clinical arthritis. Autoantibodies, such as RFs and anticitrullinated protein 
antibodies, are commonly associated with RA. Autoantibodies occur in RA that 
recognize either joint antigens, such as type II collagen, or systemic antigens, such 
as glucose phosphate isomerase. The autoantibodies potentially can contribute to 
synovial inflammation through several mechanisms, including local activation of 
complement. 
            Autoantibody titers usually do not correlate well with disease activity. 
Improvement can be associated with modest decreases in levels of RFs or 
anticitrullinated peptide antibodies, although the changes tend to be relatively 
modest and are not consistent. These observations suggest that autoantibodies, 
although they contribute to the pathogenesis of RA, are not the primary driving 
factor. 
  
 
Potential Auto-antigens in Rheumatoid Arthritis 
1. Cartilage antigens 
2. Type II collagen 
3. gp39 
4. Cartilage link protein 
5. Proteoglycans 
6. Aggrecan 
7. Citrullinated peptides 
8. Glucose-6-phosphoisomerase 
9. HLA-DR (QKRAA) 
10. Heat-shock proteins 
11. Heavy-chain binding protein (BiP) 
12. hnRNP-A2 
13. Immunoglobulins (IgG) 
 
 
CLINICAL FEATURES 
The incidence of Rheumatoid arthritis increases in 25 to 55 years of age, after that 
it plateaus till the age of 75 and then decreases.  
Patterns of onset 
A) Insidious onset: 
 RA has an insidious, slow onset over weeks to months in 55% to 65% of 
cases. The initial symptoms may be systemic or articular. 
 In some individuals, fatigue, malaise, swollen hands, and diffuse 
musculoskeletal pain may be the first nonspecific complaints, with joints 
becoming involved later. 
 Patient often can identify one joint that was involved first, quickly followed 
by others. Asymmetric initial presentations (often with more symmetry 
developing later in the course of disease) are common. 
 Morning stiffness is a cardinal sign of inflammatory arthritis that can appear 
even before pain and may be related to the accumulation of edema fluid 
within inflamed tissues during sleep. To be specific for joint inflammation, 
morning stiffness (e.g., ―difficulty moving around‖) should persist for at 
least 30 to 45 minutes before disappearing. 
 A low-grade fever without chills is rarely present. 
 A small but significant weight loss is common and reflects the catabolic 
effects of cytokines and an associated anorexia. 
B) Acute or intermediate onset: 
 8% to 15% have an acute onset of symptoms that peak within a few days. 
 Fever, suggesting an infectious process, can be a prominent sign. 
 An intermediate type of onset, in which symptoms develop over days or 
weeks, occurs in 15% to 20% of patients. 
Joint involvement 
 Initial joint involvement can be single joint (monoarticular), less than or 
equal 4 joints (oligoarticular) or polyarticular (>5 joints). 
 The joints most commonly involved first in RA are the metacarpophalangeal 
(MCP) joints, proximal interphalangeal (PIP) joints, metatarsophalangeal 
joints, and wrists. 
 Larger joints generally become symptomatic after small joints. 
 Synovitis in large joints is likely to remain asymptomatic for a longer time 
than in smaller ones, and a biopsy specimen of an asymptomatic knee often 
shows histologic evidence of synovitis. 
 
Unusual patterns or variants of disease 
a) Palindromic pattern of onset: 
 Palindromic rheumatism was described by Hench and Rosenberg in 
1942.
[41]
 
 Pain usually begins in one joint or in periarticular tissues; symptoms 
worsen for several hours to a few days and are associated with 
swelling and erythema. 
 Then, in reverse sequence, symptoms resolve, leaving no residua. 
 An intercritical period, similar to that of gout, is asymptomatic. 
 Half of patients with palindromic rheumatism go on to develop RA, 
particularly patients with HLA-DR4. 
 
 
b) Effect of Age on Onset: 
 Older individuals (≥65 years old) developing RA often present with 
stiffness, limb girdle pain, and diffuse boggy swelling of the hands, 
wrists, and forearms. 
 Individuals with onset at age 60 years or older are less likely to have 
subcutaneous nodules or RF at the onset of disease, despite the high 
prevalence of RF in the general population in this age group. 
 Generally, elderly individuals who develop RA tend to have a more 
benign course than younger patients; there is a lower frequency of 
positive tests for RF, but there is a strong association with HLA-DR4. 
The onset is slow, but the stiffness is often incapacitating. 
c) Rheumatoid Arthritis and Paralysis: Asymmetric Disease 
 Joints are typically spared on the paralyzed side, and the degree of 
protection shows a rough correlation with the extent of paralysis. 
 The protective effect on the affected side is less if a neurologic deficit 
develops in a patient who already has RA. 
 
d) Arthritis Robustus: 
 Most patients are men; their disease is characterized by proliferative 
synovitis, often with deformity, that seems to cause little pain and 
even less disability. 
 Periarticular osteopenia is unusual, whereas new bone proliferation at 
joint margins near significant erosions of bone and cartilage are 
common. 
 Bulky subcutaneous nodules develop. Subchondral cysts also develop, 
presumably from the excessive pressure developed from synovial 
fluid within a thick joint capsule during muscular effort. 
e) Rheumatoid Nodulosis: 
 Whether rheumatoid nodulosis is a variant subset of RA or a different 
entity has not been clarified. 
 The clinical picture is of a palindromic set of recurrent pain and 
swelling in different joints, radiologic subchondral bone cysts, and 
subcutaneous rheumatoid nodules. 
 Second-line drugs helped articular disease, but not other components 
of the process.
[42]
 
Course and complications of established Rheumatoid arthritis 
              The spectrum of the clinical course of RA can range from patients who 
have mild pauciarticular synovitis, negative serum RF, with few radiographic 
changes, to patients who have unrelenting pain, synovitis, joint damage, and extra-
articular manifestations. 
              Involvement of specific joints: 
a) Hand and Wrist: 
 Swelling of the proximal, but not the distal interphalangeal joints 
results in ‗spindling‘ of fingers. 
 Hyperextension of the proximal interphalangeal joints and flexion of 
the distal interphalangeal joints result in ―swan neck deformity‖. 
 Flexion of the proximal interphalangeal joints and extension of the 
distal interphalangeal joints result in ―boutonniere or button hole 
deformity‖. 
 Hyperextension of the first interphalangeal joint and flexion of the 
first metacarpophalangeal joint with a consequent loss of thumb 
mobility can occur. 
 Extensor tendon rheumatoid granulomata and tendon rupture results in 
―dropped finger‖. 
 Radial deviation of wrist and ulnar deviation of the digits often with 
palmar subluxation of proximal phalanges result in ―Z-deformity‖. 
 Wrist synovitis with median nerve entrapment can result in ―carpal 
tunnel syndrome‖. 
b) Shoulder: 
 RA of the shoulder not only affects synovium within the 
glenohumeral joint, but also involves the distal third of the clavicle, 
various bursae and the rotator cuff, and multiple muscles around the 
neck and chest wall. Presentations due to shoulder involvement are 
 Severe shoulder pain. 
 Superior subluxation of head of humerus due to rotator cuff 
weakness. 
 Rotator cuff tears or insufficiency. 
 Marked soft tissue swelling of the anterolateral aspect of the 
shoulders due to chronic subacromial bursitis. 
 Rarely, the shoulder joint may rupture, with symptoms 
resembling those of obstruction of venous return from the arm. 
c) Elbow: 
 The frequency of elbow involvement varies from 20% to 65%, 
depending on the severity of disease in the patient populations 
studied. 
 One of the earliest findings, often unnoticed by the patient, is a loss of 
full extension. 
 RA rarely manifests with severe pain in the elbow, perhaps because 
the elbow is a stable hinge joint. 
d) Ankle and Foot: 
 Swelling of the metatarsophalangeal joints results in ‗broadening‘ of 
forefoot. 
 Lateral deviation and dorsal subluxation of the toes. 
 Plantar subluxation of metatarsal heads. 
 Eversion at the hindfoot (subtalar joint).  
 Hallus valgus deformity. 
e) Hip and knee: 
 The hip is less frequently involved early in RA than in juvenile RA. 
 Symptoms of hip synovitis are pain in the lower buttock or groin. 
 About half of patients with well-established RA have radiographic 
evidence of hip disease. 
 Early in knee disease, often within 1 week after the onset of 
symptoms, quadriceps atrophy is noticeable and leads to the 
application of more force than usual through the patella to the femoral 
surface. 
 Another early manifestation of knee disease in RA is a loss of full 
extension, a functional loss that can become a fixed flexion 
contracture unless corrective measures are undertaken. 
 Flexion of the knee that has a moderate to large effusion markedly 
increases the intra-articular pressure. This increased intra-articular 
pressure may cause an outpouching of posterior components of the 
joint, producing a ―popliteal or Baker's cyst‖. 
 
f) Cervical Spine: 
 The diskovertebral joints in the cervical spine often manifest 
osteochondral destruction in RA and on lateral radiographs may be 
found to be narrowed. 
 There is significant pain, but passive range of motion in the absence 
of muscle spasm may be normal. 
 The atlantoaxial joint is prone to subluxation in several directions. 
 The earliest and most common symptom of cervical subluxation is 
pain radiating up into the occiput. Two other serious, but less 
common, clinical patterns are as follows:   
 1.     Slowly progressive spastic quadriparesis, frequently with 
painless sensory loss in the hands  
   2.     Transient episodes of medullary dysfunction associated with 
vertical penetration of the dens and probable vertebral artery 
compression; paresthesias in the shoulders or arms may occur during 
movement of the head 
 
 
g) Thoracic, Lumbar, and Sacral Spine: 
 The thoracic, lumbar, and sacral portions of the spine are usually 
spared in RA. 
 The exceptions are the apophyseal joints; rarely, synovial cysts at the 
apophyseal joint can impinge as an epidural mass on the spinal cord, 
causing pain, neurologic deficits, or both. 
h) Temporomandibular Joint: 
 The temporomandibular joint is commonly involved in RA.  Histories 
reveal that 55% of patients have jaw symptoms at some time during 
the course of their disease. 
 Physical examination of the rheumatoid patient should include 
palpation of the temporomandibular joint for tenderness and 
auscultation for crepitus. 
 Occasionally, patients have acute pain and an inability to close the 
mouth, necessitating intra-articular glucocorticoid therapy to suppress 
the acute process. 
 Temporomandibular joint abnormalities are common in 
nonrheumatoid populations. The only specific findings for RA in the 
temporomandibular joint are erosions and cysts of the mandibular 
condyle detected by CT or MRI. 
 There is no correlation between clinical and CT findings of the 
temporomandibular joint in RA.
[43]
 
i) Cricoarytenoid Joints: 
 Careful histories may reveal hoarseness in 30% of rheumatoid patients 
due to involvement of Cricoarytenoid Joints. 
 Asymptomatic cricoarytenoid synovitis occasionally may lead to 
aspiration of pharyngeal contents, particularly at night. 
j) Ossicles of the Ear: 
 Many rheumatoid patients experience a decrease in hearing as a result 
of conductive hearing loss. 
 This is due to erosions and shortening of the ossicles produced by the 
erosive synovitis in RA patients, not due to ankylosis. 
k) Sternoclavicular and Manubriosternal Joints: 
 Sternoclavicular and manubriosternal joints, both possessing 
synovium and a large cartilaginous disk, are often involved in RA. 
 Because of their relative immobility, there are few symptoms. 
 Patients occasionally complain of experiencing pain in 
sternoclavicular joints, while lying on their sides in bed. 
 Manubriosternal involvement is almost never clinically important, 
although by tomographic criteria it is common in RA. 
 
Extra-articular Complications of Rheumatoid Arthritis 
             Generally, the number and severity of extra-articular features vary with the 
duration and severity of the disease. Several of these features may be related to 
extra-articular foci of an immune response,
[44]
 based on evidence of independent 
and qualitatively different production of RF in the pleural space, pericardium, 
muscle, and even meninges. 
             These patients with systemic immune responses have true rheumatoid 
disease, not just RA. 
              Extra-articular manifestations of RA are associated with excess 
mortality.
[45] 
 
Following are the extra-articular manifestations of Rheumatoid arthritis. 
A) Skeleton: 
 RA can be associated with generalized osteopenia and osteoporosis 
owing to the 
 Effects of drugs (especially corticosteroids) 
 Cytokine-induced and RANKL-induced activation of 
osteoclasts. 
 And the fact that certain groups of patients with the disease, 
especially postmenopausal women, have other risk factors that 
enhance the potential for bone loss. 
 Bone densitometry should be performed routinely in patients with RA, 
and treatment with bisphosphonates should be considered as an 
adjunct to therapy. 
 
 
 
 
B) Muscles: 
 More recent studies have pointed to at least five different types of 
muscle disease in RA, although clinically relevant active myositis is 
uncommon: 
1. Diminution of muscle bulk with atrophy of type II fibers 
2. Peripheral neuromyopathy, usually due to a mononeuritis 
multiplex 
3. Steroid myopathy 
4. Active myositis and muscle necrosis with foci of endomysial 
mononuclear cell infiltration 
5. Chronic myopathy resembling a dystrophic process, probably 
the end stage of inflammatory myositis 
 In some patients, the lymphocytes in muscle synthesize IgM RF, 
emphasizing the systemic nature of RA. 
 The patchy ―nodules of myositis‖ contain plasma cells and 
lymphocytes. 
 
C) Skin: 
 The most frequently recognized skin lesion in RA is the rheumatoid 
nodule, but there are several other manifestations as well. 
 The mature rheumatoid nodule has a central area of necrosis 
rimmed by a corona of palisading fibroblasts that is surrounded 
in turn by a collagenous capsule with perivascular collections of 
chronic inflammatory cells. 
 Occurring in 15% to 20% of patients with definite or classic 
RA, nodules are found most often on extensor surfaces or 
pressure points, such as the olecranon process and the proximal 
ulna. 
 Rheumatoid nodules can be formed in sacral region, occipital 
region, vocal cords, heart, lung, vertebral bodies, sclera, and in 
CNS involving leptomeninges more than parenchyma leading 
to complications in respective regions. 
 ―Senile‖ purpura resulting from skin atrophy and capillary fragility is 
especially common in patients treated with glucocorticoids. 
 Palmar erythema is common. 
 Manifestations of vasculitis range from occasional nail fold infarcts to 
a deep, erosive, scarring pyoderma gangrenosum. 
 Palpable purpura in rheumatoid patients is often related to a reaction 
to a drug that the patient is taking, but can be primary and a direct 
function of the severity of articular disease. 
 Livedo reticularis, the lacy, dusky purple, asymptomatic discoloration 
seen on the extremities, is believed to signify a deep dermal 
vasculopathy. 
 Cutaneous sinuses near joints develop rarely in seropositive patients 
with long-standing disease and positive tests for RF. 
D) Eye: 
 Keratoconjunctivitis sicca as a component of sicca complex 
(Keratoconjunctivitis sicca, xerostomia and salivary gland 
enlargement) of Sjögren's syndrome. 
 Scleritis, episcleritis and scleromalacia perforans. 
 Glaucoma. 
 
E) Infection: 
 The incidence of infections as a complication of RA has paralleled the 
use of glucocorticoids, biologics, and immunosuppressive agents. 
 Pulmonary infections, skin sepsis, and pyarthrosis are the most 
common infection in RA.
 [46] [47]
 
F) Cancer: 
 There is an increased risk for malignancy in RA patients particularly 
 Lymphoma. 
 Lung carcinoma- commonly bronchoalveolar variety. 
 Two to three times higher risk of Hodgkin's disease, non-
Hodgkin's lymphoma, and leukemia than the normal 
population; this is independent of immunosuppressive therapy. 
G) Hematological abnormalities: 
 A mild normocytic normochromic anemia that correlates with ESR 
elevation and the activity of the disease. 
 Thrombocytosis. 
 Eosinophilia and mild leukocytosis. 
H) Vasculitis: 
 Rheumatoid vasculitis affects a subset of patients with established, 
often severe, RA with a prevalence of less than 5% of all cases. 
  Variables associated with the development of rheumatoid vasculitis 
include the following: 
 Male gender 
 High titers of RF in serum 
 Hypocomplementemia 
 Joint erosions 
 Subcutaneous nodules and other extra-articular features 
 Long-standing disease 
 Circulating cryoglobulins 
 Clinical vasculitis usually takes one of the following forms: 
 Distal arteritis (including from splinter hemorrhage, nail fold 
infarcts, and gangrene) 
 Cutaneous ulceration (including pyoderma gangrenosum) 
 Peripheral neuropathy (mononeuritis multiplex) 
 Arteritis of viscera, including heart, lungs, bowel, kidney, liver, 
spleen, pancreas, lymph nodes, and testis 
 Palpable purpura 
I) Renal disease: 
 The kidney is rarely involved directly in RA, but often is 
compromised indirectly by therapy. 
 Amyloidosis: AA amyloidosis, along with vasculitis and sepsis, is one 
of the most important life-threatening complications of RA. 
 Renal papillary necrosis: related to Phenacetin abuse. 
 NSAID related renal failure. 
 Membranous nephropathy: related to therapy with gold salts and 
penicillamine in treatment of RA. 
 Rarely, a focal necrotizing glomerulitis is seen in patients dying with 
RA and disseminated vasculitis. 
 
 
J) Pulmonary disease: 
There are at least six forms of lung disease in RA, as follows:    
1) Pleural disease:  
      Characteristics of exudative rheumatoid effusions are as 
follows: 
 Glucose, 10 to 50 mg/dL 
 Protein, greater than 4 g/dL 
 Cells (mononuclear), 100 to 3500/mm3 
 Lactate dehydrogenase, elevated 
 CH50, depressed 
      The low glucose concentrations are of interest. An 
impaired transport of glucose into the pleural space seems to 
be the cause of this. 
2) Interstitial fibrosis  
3) Nodular lung disease  
4) Bronchiolitis obliterans with organizing pneumonia  
5) Arteritis, with pulmonary hypertension  
6) Small airways disease 
K) Cardiac complications: 
           In patients with RA, Cardiovascular disease is the most common 
cause of mortality, primarily due to myocardial infarction and congestive 
heart failure. 
          Following are the cardiac complications: 
 Atherosclerosis 
       There are multiple risk factors for coronary artery disease in RA 
patients in addition to the risk factors that are relevant in the general 
population. 
 Patients with prolonged RA have more atherosclerosis than 
patients of the same age with more recent disease onset.
[48]
 
 Even after controlling the traditional risk factors of 
atherosclerosis (like diabetes, hypertension, 
hypercholesterolemia, obesity, and cigarette smoking), the 
incidence of carotid atherosclerosis and coronary artery 
disease is higher in patients with RA.
[49] 
 Presence of 
increased inflammatory mediators in serum in this patients 
appears to be responsible for this. 
 It also is apparent that, all else being equal, tobacco smoking is 
an important factor in augmenting early atherosclerosis in RA 
patients.
[50]
 
 Other cardiac complications of RA are 
 Pericarditis 
 Myocarditis 
 Endocardial inflammation 
 Conduction defects 
 Coronary arteritis 
 Granulomatous Aortitis or valvular disease. 
 
 
 
 
 
 
DIAGNOSIS 
             Criteria to establish the diagnosis of RA are based on an effective clinical 
history and physical examination, laboratory tests, and exclusion of other 
diagnoses. 
2010 AMERICAN COLLEGE OF RHEUMATOLOGY/EUROPEAN LEAGUE AGAINST RHEUMATISM 
(ACR-EULAR) CLASSIFICATION CRITERIA FOR RHEUMATOID ARTHRITIS* 
Criteria Score 
Joint Involvement 
1 large joint** 0 
2-10 large joints 1 
1-3 small joints*** (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
10 joints (at least 1 small joint) 5 
Serology (at least 1 test result needed for classification) 
Negative RF and negative ACPA 0 
Low-positive RF or low-positive ACPA 2 
High-positive RF or high-positive ACPA 3 
Acute-Phase Reactants (at least 1 test result needed for classification) 
Normal CRP and normal ESR 0 
Abnormal CRP and abnormal ESR 1 
Duration of Symptoms 
Less than 6 weeks 0 
6 or more weeks 1 
*Target population: patients who have at least 1 joint with definite clinical synovitis in whom the 
synovitis is not better explained by another disease.  
** Large joints include shoulders, elbows, hips, knees, and ankles.  
*** Small joints refers to the metacarpophalangeal joints, proximal interphalangeal joints, second 
through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists.  
RF = rheumatoid factor; ACPA = anticitrullinated protein antibody; CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate. 
       Application of ACR-EULAR criteria gives a score of 0-10. A score of ≥6 
fulfills the requirement for definite RA. 
           Initial laboratory tests often show the results in the following list (essential 
tests are indicated with an asterisk (∗). The other tests listed are largely of academic 
interest and should not be ordered routinely.  
   •     Normal white blood cell count and differential∗ 
   •     Thrombocytosis∗ 
   
•     Mild anemia (hemoglobin 10 g/dL), normochromic and either normocytic or 
microcytic∗ 
   •     Normal urinalysis∗ 
   
•     ESR 30 mm/hr or greater and C-reactive protein level greater than 0.7 
pg/mL∗ 
   •     Normal renal, hepatic, and metabolic tests∗ 
   
•     Normal serum uric acid level 
 
   
•     Positive RF test (about 70% to 80% of patients; present in many normal 
individuals, patients with other rheumatic diseases, and individuals with 
chronic infections)∗ 
   
•     Anticitrullinated protein antibody (about 80% to 90% of patients; can be 
seen in other diseases, including active tuberculosis) (especially useful in 
early synovitis)∗ 
              Some investigators are convinced that anticitrullinated protein antibody 
will replace RF in the future as the autoantibody most useful in diagnosis. At this 
time, until it is cost-effective, it can be used to supplement RF in the presence of a 
strong clinical suspicion.  
   
•     Other autoantibodies (commonly found but with limited differential 
diagnosis utility, including antinuclear antibody, SS-A, SS-B) 
   •     Polyclonal gammopathy as determined by serum protein electrophoresis 
   •     Normal or elevated serum complement level 
   
•     Negative antineutrophil cytoplasmic antibody and anti–double-stranded 
DNA antibody tests 
    
•     ―Typical‖ arthrocentesis, when obvious fluid is present, in RA reveals the 
following:  
   
  Joint fluid is straw-colored, is slightly cloudy, and contains 
many flecks of fibrin 
   
  5000 to 25,000 white blood cells/mm3, and at least 50% of 
these are polymorphonuclear leukocytes 
     No crystals 
   
  Complement C4 and C2 levels are depressed, but C3 level can 
be normal 
     Normal synovial fluid glucose level 
     Cultures are negative. 
 
 
 
 
COURSE OF THE DISEASE 
        Epidemiologic studies suggest that the disease is not changing, but that 
earlier, more effective treatment has diminished morbidity.  
         There are now well-tested criteria for clinical remission.  
         One composite system using the Disease Activity Score is a mathematical 
method that includes swollen and tender joints, ESR, and patient assessments of 
global health (DAS28 scoring). Notably, this criterion does not mean that the 
patient truly has complete remission without any evidence of synovitis. 
         The American College of Rheumatology criteria require absence of joint 
tenderness, fatigue, joint pain, joint swelling, and morning stiffness, along with a 
normal ESR for the patient to be called under remission. 
     Although the initial radiographic score is, as expected, a powerful predictor of 
subsequent radiographic damage, a high titer of RF and anticitrullinated protein 
antibodies continue to be powerful predictors of deteriorating radiographic damage 
in subjects receiving conventional therapy.
[51]
 
        It has been shown in several studies that the Health Assessment Questionnaire 
is an excellent predictor of work disability and mortality 
[52]
 and can be discrepant 
from damage measured by radiographs. 
      Mortality: 
 In well-established RA, the median life expectancy is less than in 
control populations.
 [53] [54]
 
 Infection, renal disease, and respiratory failure traditionally have been 
the primary factors contributing to excess mortality in RA patients, 
although it has been belatedly recognized that congestive heart 
failure, ischemic heart disease, and peripheral atherosclerosis 
deserve the appellation as the prime killers of rheumatoid 
arthritis patients. 
 This increased incidence of cardiovascular events in RA patients 
is independent of traditional risk factors, such as age, sex, 
smoking status, diabetes mellitus, hypercholesterolemia, systolic 
blood pressure, and body mass index.
[55]
 
 The generally accepted explanation is that inflammatory cytokines 
that are produced in excess in RA (e.g., TNF-α, platelet-derived 
growth factor) have the capacity to activate endothelial and 
subendothelial myofibroblasts, and numerous inflammatory cells are 
found in atheromatous plaques. 
 Ultrasonography has shown that RA patients have greater 
thickness of the common carotid and femoral arteries than do 
healthy controls, a finding that was independent of glucocorticoid 
therapy, but related to the duration and severity of RA.
[56]
 
 The following factors and pathobiologic mechanisms could contribute 
to atherosclerosis in RA: 
 Immune complex–mediated endothelial damage. 
 Acute-phase reactants (C-reactive protein and serum 
amyloid A, both of which have pro-inflammatory 
activity). 
 Inflammatory cytokines. 
 High expression of endothelial cell leukocyte adhesion 
molecules. 
 Medications (e.g., steroids). 
 Prothrombotic factors (e.g., increased platelets, 
fibrinogen, and thromboxane). 
 Endothelial cell dysfunction induced by inflammation. 
 Considerations of therapy in rheumatoid patients must factor in 
the effects on atherogenesis. These considerations might include, in 
patients with an unfavorable vascular profile, 
 Supplementation with omega-3 fatty acids in the diet. 
 Early use of HMG-CoA Reductase inhibitors (statins that, 
in addition to lipid-lowering effects, reduce C-reactive 
protein). 
 Attempts to reduce elevated levels of homocysteine 
induced by methotrexate. 
 Avoidance of cyclosporine. 
 Aggressive weight-loss disciplines and  
 Smoking cessation. 
 In addition to cardiovascular causes of death associated with RA are 
causes of death due to the complications (articular and extra-articular) 
of RA and to side effects of therapy. 
 Potentially morbid articular complications include the various 
forms of atlantoaxial subluxation, cricoarytenoid synovitis, and 
sepsis of involved joints. 
 Extra-articular complications directly causing a higher mortality 
include Felty's syndrome, Sjögren's syndrome, pulmonary 
complications, and diffuse vasculitis. 
Factors that correlate with a poorer prognosis and greater likelihood of joint 
destruction in RA: 
 Positive RF in serum.[57] 
 Positive anticitrullinated protein in serum. 
 Rheumatoid nodules.[58] 
 Elevated Health Assessment Questionnaire level of disability.[59] 
 Depression.[60] 
 Persistent ESR elevation (serving as a surrogate for disease control). 
 Presence of the shared epitope (QKRAA) on class II major 
histocompatibility genes. 
  
     
 
  
 
 
TREATMENT: 
         The American College of Rheumatology (ACR) treatment guidelines call for 
a comprehensive approach to the patient with involvement of the primary care 
provider and the rheumatologist, and provide a general guideline for starting, 
changing, or adding DMARDs to the treatment of a patient with active disease 
A) Disease modification therapy: 
 DMARD therapy generally begins with the initiation of therapy with 
the traditional small molecules, such as 
 methotrexate (MTX), 
 hydroxychloroquine (HCQ), or  
 sulfasalazine (SSZ) 
 Although other small molecule treatments exist (e.g., azathioprine, 
gold salts, penicillamine, cyclosporine), these agents are used 
infrequently and usually reserved for patients refractory to other 
therapy or with idiosyncratic side effects with the other agents. 
 
 
 Newer generation DMARDs: 
 Leflunomide 
 TNF-α inhibitors adalimumab, etanercept, and infliximab 
 Interleukin (IL)-1 receptor antagonist Anakinra. 
 Selective costimulation modulator Abatacept. 
 The B cell–targeted approach using Rituximab (RTX). 
 The IL-6 receptor antibody Tocilizumab 
          These agents have been well studied in clinical trials showing 
efficacy alone or in combination with traditional therapies. 
B) Adjunctive drug therapy: 
 Glucocorticoid therapy 
 Long term low dose (5-10mg/day of prednisolone or its 
equivalent) therapy as adjunct to DMARDs. 
 In low to moderate doses before the effect of DMARD therapy 
starts, which often take few weeks to months. 
 1 to 2 weeks of high dose glucocorticoids to treat the acute 
disease flares. 
 Intraarticular injection of intermediate acting glucocorticoids 
(like triamcinolone acetonide) to treat few actively inflamed 
joints. 
 Non-steroidal anti-inflammatory drugs (NSAIDs) 
           NSAIDs are the most often used and are a very effective 
adjunctive therapy in RA, providing analgesic and anti-inflammatory 
benefits. The anti-inflammatory effect is due to nonselective 
inhibition of COX-1 and COX-2. 
         Long term use should be minimized to prevent adverse effects 
like gastritis, peptic ulcer disease and renal failure. 
 Analgesics  
 Acetaminophen. 
 Codeine or other narcotic derivatives. 
 
 
METHODS OF ASSESSING DISEASE ACTIVITY OF RHEUMATOID    
ARTHRITIS AND RESPONSE TO THERAPY: 
          Many quantitative approaches exist for this purpose. 
1) ACR response criteria. 
2) DAS/DAS28. 
3) HAQ (Health Assessment questionnaire). 
4) Simplified Disease Activity Index (SDAI). 
5) Clinical Disease Activity Index (CDAI). 
 
 
 
 
 
 
 
 
DAS28 (DISEASE ACTIVITY SCORE 28): 
          This scoring system integrates the measures of physical examination, acute 
phase response, and general health status as assessed by patient on visual analogue 
scale. 
           DAS28 is calculated by using the formula 
DAS 28 = 0.56√TJC + 0.28√SJC + 0.70 (log ESR) + 0.014 GH 
Where, 
 TJC is tender joint count 
 SJC is swollen joint count 
 GH is general health status as assessed by patient on visual analogue scale 
(VAS). 
         General health status is assessed by patient on Visual Analogue Scale 
(VAS) marked from 0 to 100, where ‗0‘ indicating very good health status and 
‗100‘ corresponding to very poor health status. As the number increases from ‗0‘ 
towards ‗100‘, it indicates decreasing health status. 
 
 
Joints assessed in DAS28: 
 Total 28 joints will be assessed for tenderness and swelling. 
 Proximal interphalangeal joints of hands (5+5), distal interphalangeal joints 
of hands (5+5), wrist joint (1+1), Elbow joint (1+1), shoulder joint (1+1) and 
knee joint (1+1). 
       
              
        This scoring system provides absolute indication of RA disease activity on a 
scale of 0.49 to 9.07. 
DAS28 DISEASE ACTIVITY 
>5.1 High 
3.2-5.1 Moderate 
2.6-3.1 Low 
<2.6 Remission 
    
       Disease response to therapy can be assessed by using DAS28 in RA patients 
by applying EULAR Response Criteria as follows, 
DAS28 at 
endpoint 
Improvement in DAS28 from baseline 
>1.2 >0.6 and <1.2 <0.6 
<3.2 Good  Moderate none 
3.2-5.1 Moderate Moderate None 
>5.1 Moderate Moderate None  
 
AIMS AND OBJECTIVES OF THE STUDY 
 
A) To determine whether carotid artery intima media thickness (CIMT)  is  
advanced in patients with Rheumatoid arthritis (RA), as  compared to 
healthy controls.  
B) To study the correlation if any between Carotid Intima Media Thickness 
(CIMT) and duration of Rheumatoid arthritis. 
C) To study the correlation if any between Carotid Intima Media Thickness 
(CIMT) and activity of Rheumatoid arthritis.  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
SETTING: 
              Rheumatology outpatient clinic, Government Rajaji Hospital (GRH), 
Madurai, Tamilnadu. 
DESIGN OF THE STUDY: 
              Matched cross sectional study. 
PERIOD OF STUDY: 
              April2012 – October 2012. 
DETAILS OF STUDY MATERIALS AND METHODS:  
             The study was performed in 40 Rheumatoid arthritis (RA) patients and 40 
healthy control subjects.  
              The RA patients were selected from consecutive patients attending 
Rheumatology outpatient clinic at Govt. Rajaji Hospital (GRH), Madurai, who 
were diagnosed according to 2010 American College of Rheumatology-European 
League against Rheumatism (ACR-EULAR) criteria. 
               40 healthy controls were selected from among the people who were 
attending local health-check program at GRH Madurai. 
                Written informed consent was taken from all cases and controls. 
                 The following exclusion criteria were used to avoid confounding by 
other known risk factors for atherosclerosis: 
a) Hypertension (BP > 140/90 mmHg) or use of antihypertensive 
medications. 
b) Hypercholesterolemia (Total cholesterol>240mg/dl, LDL >160 mg/dl, 
triglycerides >200 mg/dl) or use of lipid lowering medication. 
c) Diabetes Mellitus (diagnosed according to WHO criteria) or use of 
anti-diabetic medication. 
d) History of coronary artery disease. 
e) History of cerebrovascular accidents (CVA). 
           All the subjects included in our study (both cases and controls) were not 
known cases of IHD (ischemic heart disease), Diabetes Mellitus, or Hypertension 
and did not suffer any cerebrovascular events in the past.  And also did not have 
any evidence of hepatic or renal impairment. 
            The RA patients included in the study as subjects were divided in to three 
groups based on the duration of disease. These were:  
 Group-1: Those subjects who had RA for less than 2 years. 
 Group-2: Those subjects who had RA between two to five years. 
 Group-3: those subjects who had Ra for more than 5 years. 
            Another 40 healthy (age and sex matched) subjects were taken into group-4 
as controls. 
            All the RA patients included in the study were evaluated for their disease 
activity using the disease activity score ―DAS28‖.  This score is calculated by 
using the formula 
                            DAS 28 = 0.56√TJC + 0.28√SJC + 0.70 (log ESR) + 0.014 GH 
            Where,  
 TJC: Tender joint count. 
 SJC: Swollen joint count. 
 GH: General health status as assessed by patient on visual analogue 
scale (VAS). 
              All the subjects including the controls were evaluated for carotid intima 
media thickness by using carotid ultrasonography. Carotid ultrasonography was 
carried out by skilled radiologist by using gray scale ultrasonography and then 
followed by colour flow imaging. 
         Carotid intima media thickness (CIMT) was measured in common carotid 
artery bilaterally by examining throughout common carotid artery up to 2cm 
proximal to bifurcation. CIMT measurement was taken at the site of greatest 
thickness, and three readings were taken from each side at different points within 
the region of interest. All measurements were taken in diastole, measured in phase 
when the lumen diameter is at its smallest and IMT at its largest. The mean value 
of 6 readings (3 from each side) was taken as the final CIMT for evaluation. 
           The results obtained were subjected to one way ANOVA test for statistical 
analysis. 
 
 
 
 
 
  
 
 
 
 
 
 
OBSERVATIONS AND RESULTS 
A. Characteristics of the cases and controls included in the study: 
Table – 1 
Distribution of cases in relation to gender 
Sex No. of cases Percentage 
Male 12 30 
Female 28 70 
Total 40 100 
 
         Total of 40 cases were enrolled for the study. Among them 12 cases (30%) 
were males and 28 cases (70%) were females. So, females form the major number 
in our study. 
         Control subjects were also in similar distribution as that of cases in relation to 
total number and gender distribution. 
 
  
 
 
 
 
 
Table – 2 
Distribution of cases and controls in relation to age 
Age in years No. of Cases No. of Controls 
< 30 4 3 
31 - 40 13 11 
41 – 50 11 16 
51 -60 11 10 
> 60 1 0 
Total 40 40 
Mean age 
S.D 
43.9yrs 
10.52 
44.37yrs 
9.41 
 
        Among the 40 cases, majority of are between 3
rd 
and 5
th 
decade and the 
controls share the same character. Mean age for cases is 43.9 years and mean age 
for controls is 44.375years. 
  
 
 
 
 
 
B. The study comprised of three groups among the cases based on the 
duration of the disease and the healthy control subjects were taken as 
group-4.     The following were the observations: 
Table – 3 
Three groups according to Duration of disease 
Duration of 
symptoms 
No. of cases Percentage 
GROUP-1 
(< 2 years) 
8 20 
GROUP-2 
(2 – 5 years) 
24 60 
GROUP-3 
( > 5 years) 
8 20 
Total 40 100 
 
 
  
 
 
 
 
 
Table – 4 
Age Distribution in each Group of cases 
Age in years Group-1 Group-2 Group-3 
< 30 0 3 1 
31 - 40 4 8 1 
41 – 50 3 4 4 
51 -60 1 8 2 
> 60 0 1 0 
Total 8 24 8 
 
        
 
 
  
 
 
 
 
 
 
Table – 5 
Sex distribution in each group 
Sex Group-1 Group-2 Group-3 
Male 3 7 2 
Female 5 17 6 
Total 8 24 8 
 
     
  Out of 40 RA cases, 8 cases (20%) were present in group-1, 24 cases (60%) were 
present in group-2, and 8 cases (20%) were present in group-3 (Table-3).  And the 
majority of patients were females in all the three groups.     
 
 
 
 
 
Table -6 
Mean age distribution in each group 
GROUPS Age in years 
Range mean 
GROUP-1 33-52 42.5±7.05 
GROUP-2 27-65 46.39±11.73 
GROUP-3 19-55 43.5±11.08 
GROUP-4 (controls) 20-60 44±9.41 
 
The mean age of all the three groups among cases was comparable. Also the mean 
age of cases and controls were comparable. 
 
 
 
 
 
C. The groups were compared for various biochemical parameters. 
Table – 7: Biochemical parameters in each group 
BIOCHEMICAL 
PARAMETERS 
Group I 
< 2 years 
Group 2 
2 – 5 years 
Group 3 
> 5 years 
Control 
Mean SD Mean SD Mean SD Mean SD 
Blood sugar 84.0 14.57 101.9 19.99 87.1 23.18 89.2 22.17 
Blood Urea 25.0 7.65 25.96 7.01 29.25 8.56 27.77 9.07 
Creatinine 0.875 0.116 0.846 0.118 0.887 0.181 0.893 0.135 
Cholesterol 159.3 21.82 167.8 22.76 169.0 20.2 168.5 16.99 
TGL 145.8 11.81 150..2 15.25 156.1 21.3 153.4 11.9 
LDL 88.1 13.54 92.46 15.38 82.62 13.8 92.6 13.2 
VLDL 33.4 3.62 36.00 5.23 37.3 3.28 35.0 3.59 
HDL 39.3 2.82 39.7 3.00 39.4 2.13 39.3 2.59 
 
      All the groups were comparable – including the mean values of sugar and lipid 
profile (atherogenic biochemical risk indices). 
  
 
 
 
 
 
 
 
D. Disease duration and activity of disease are compared in RA patients 
TABLE – 8 
DAS28 vs Duration of disease. 
Groups according to 
Duration of disease 
DAS28 
Mean SD 
Group-1 
(< 2 years) 
5.19 0.78 
Group-2 
(2 – 5 years) 
4.99 1.28 
Group-3 
(> 5 years) 
4.54 0.87 
 
The disease activity as per DAS28 was comparable in all three groups with a p 
value of >0.05 
 
 
  
 
 
 
 
 
Table -9 
Disease activity and duration of disease compared 
Duration of 
disease 
Disease activity (No. of cases) 
Low Moderate High 
Group-1 
(<2years) 1 4 4 
Group-2 
(2-5years) 3 12 9 
Group-3 
(>5years) 0 6 2 
Total 4 22 15 
 
      Overall, majority of cases in our study were in moderate disease activity. In 
group-1, patients with moderate and high disease activity were equal in number. In 
both group-2 and group-3, majority were in moderate disease activity. 
 
  
 
 
 
 
 
 
E. Carotid intima media thickness (CIMT): case vs. control 
TABLE – 10 
CIMT-case vs. control 
STUDY GROUPS CIMT(mm) 
Mean SD 
Cases 0.692 0.136 
Controls o.56 0.046 
p value < 0.001  (Statistically significant) 
 
      Mean value of CIMT was significantly higher in cases compared to control 
group with a significant p-value of <0.001. 
 
 
 
 
 
  
 
 
 
F. Carotid intima media thickness (CIMT) compared with duration of 
disease 
Table-11: CIMT vs. Duration of disease 
 
 
 
 
 
 
 
 
 
 
         The CIMT mean value was 0.60±0.10 mm for group-1, 0.68±0.12 mm for 
group-2 and 0.80±0.14mm for group-3. The increase in CIMT with duration of 
disease was significant (with a p value of 0.012, which is statistically significant). 
Duration of 
disease 
CIMT(mm) 
Mean SD 
Group-1 
(< 2 years) 
0.60 0.10 
Group-2 
(2 – 5 years) 
0.68 0.12 
Group-3 
(> 5 years) 
0.80 0.14 
p value 0.012 (Statistically significant) 
  
 
 
 
 
 
G. CIMT compared with Activity of the disease. 
Table – 12: Activity of RA vs. CIMT 
Disease activity CIMT(mm) 
Mean SD 
Group-A(Low)        0.70 0.08 
Group-B(Moderate) 0.69 0.12 
Group-C(High)           0.68 0.15 
P value 0.978 (statistically not significant) 
        Based on DAS28 score, the cases were again grouped as 3 groups.  
 Group-A: with low disease activity with DAS28 of 2.6-3.1 
 Group-B: with moderate disease activity with DAS28 of 3.2-5.1. 
 Group-C: with high disease activity with DAS28 of >5.1. 
         In these groups, the relationship between CIMT and disease activity was 
studied (table-12). The comparison between various sub-groups A, B and C, in 
relation to CIMT was found to be statistically not-significant with p value >0.05. 
 
  
 
 
 
 
 
 
H. Correlation of CIMT with CRP positivity in RA patients.                     
Table-13:  CRP in cases 
CRP Number of 
cases 
Percentage 
positive 17 42.5% 
negative 23 57.5% 
total 40 100% 
  
Table-14: Mean CIMT vs. CRP positivity status. 
CRP CIMT 
Mean SD 
Positive 0.72 0.14 
Negative 0.66 0.12 
P value 0.176 (statistically not 
significant) 
 
    Another observation made in our study is out of 40 cases of RA, 17 cases 
(42.5%) were reported to be CRP-positive. On comparing the mean of CIMT 
of CRP-positive cases with CRP-negative cases, CRP positive cases had a 
relatively high mean CIMT value than CRP-negative patients but with p 
value of 0.176 which is statistically not significant. 
 
 
 
 
 
 
 
 
 
DISCUSSION 
      
  Atherosclerosis is a disease of the arterial system of our body, in which the blood 
vessel wall will become thickened and hardened by "plaques‖. The composition of 
atherosclerotic plaque is cholesterol and other lipids, inflammatory cells, and 
calcium deposits. 
       Atherosclerosis is an inflammatory disease. There are striking similarities 
between the inflammatory and immunological mechanisms operating in 
atherosclerotic plaque and in rheumatoid synovitis. The common 
pathophysiological features in the affected tissues include an abundance of 
activated macrophages which release or induce release of inflammatory mediators, 
including cytokines (e.g., IL-1 and TNF), adhesion molecules with matrix 
metalloproteinases, growth factors and T-cell infiltrates.  
          Both atherosclerosis and Rheumatoid arthritis are associated with elevated 
levels of acute phase reactants – C-reactive protein (CRP), serum amyloid A, ESR, 
fibrinogen, and secondary phospholipase 2
25
. 
         It has been reported in many studies that the accelerated atherosclerosis 
associated with Rheumatoid arthritis to be independent of traditional risk factors of 
atherosclerosis. 
     In the present study, hypertension, diabetes mellitus and hyperlipidemia were 
exclusion criteria. The atherogenic biochemical parameters (like blood sugar, 
cholesterol, triglycerides, LDL, and VLDL) that were estimated in our study 
subjects were within normal range (Table-7). So, our study was free of these 
traditional risk factors for accelerated atherosclerosis.  
       CIMT is a reliable marker for coronary atherosclerosis and peripheral vascular 
disease
30
. The following table shows normal carotid artery intima media thickness 
(CIMT) based on multiple studies, according to age and gender. 
AGE 
(years) 
Right CIMT (mm) Left CIMT (mm) 
Men women Men Women 
<30 0.39-0.48 0.39-0.43 0.42-0.49 0.30-0.47 
31-40 0.42-0.50 0.42-0.49 0.44-0.57 0.44-0.51 
41-50 0.46-0.57 0.44-0.53 0.50-0.61 0.46-0.57 
>50 0.46-0.62 0.50-0.59 0.53-0.70 0.52-0.64 
         According to Homa et al, the intima media thickness of common carotid 
artery (measured at areas devoid of plaque) increases linearly with age from 0.48 
mm at 40 years of age to 1.02 mm at 100 years of age (following a formula 0.009 
x age + 0.116 mm)
24
. 
        The mean age of the present study (including control group) was 44.13years. 
So, expected CIMT is approximately 0.513 mm. In the present study, Carotid 
intima media thickness (CIMT) in the control group was 0.56 ± 0.046 mm (almost 
nearing the homa equation, i.e., 0.513 mm) whereas the Carotid intima media 
thickness in RA patients (cases) was higher, i.e., 0.692 ± 0.136 mm (Table-10) 
with  p value < 0.001. A similar observation has also been shown by Gonzalez et 
al
31
 and Alkabbi et al
32
 in their respective studies. In a recent Indian study, 
Mahajan et al have similar observations
20
. All the studies (including the 
present study) show a significantly higher value of CIMT in RA subjects than the 
normal population. 
         The mean CIMT was significantly higher in group-3 (disease >5 years) when 
compared to group-1 and 2 with p value of 0.012 which is statistically significant 
(Table-11). This clearly suggests that CIMT increases with increase in duration of 
Rheumatoid arthritis. Gonzales et al in their study had found disease duration as 
one of the best predictor for the development of severe morphologic expression of 
atherosclerotic disease
31
. DelRincon et al
33 
and Mahajan et al
20
 also had similar 
observations. This may be due to more years of exposure to increased 
inflammation
5,10,13-16
, and other factors like increased arterial stiffness
33
 and 
prothrombotic markers in RA patients
35
. Role of inflammation as a basic 
pathogenic mechanism in atherosclerosis is well known
33
. 
           The mean values of CIMT for low, moderate and high disease activity sub-
groups were 0.70 ± 0.08mm; 0.69 ± 0.12mm and 0.68 ± 0.15 mm respectively. 
These values when compared with each other were found to be statistically not-
significant (p value > 0.05) (Table-12), suggesting no correlation between disease 
activity at a particular time and carotid intima media thickness. Similar 
observations were presented by Jonsson
27
 and Roman et al
28
.  
         On correlating the CIMT with CRP (an important marker of inflammation)  
in RA cases, the mean CIMT was comparatively higher in CRP positive cases than 
in CRP negative patients, but with a p value >0.05 which is statistically not 
significant.  
       So, rheumatoid arthritis which is a chronic inflammatory disease mainly 
involving joints has been found to have accelerated atherosclerosis when compared 
to age and sex-matched controls. 
          The study also shows a significant, i.e., directly proportional relation 
between carotid intima media thickness to longer duration of disease. 
          But this study did not show significant relationship between activity of 
disease and carotid intima media thickness. 
         However, in view of the relation to duration of disease, the physicians should 
regularly screen the established RA patients so as to identify the evidence of 
atherosclerosis and manage it earlier.  
         Prevention of cardiovascular disease in RA requires a combined approach 
incorporating cardiovascular risk factors screening and management, effective and 
sustained control of RA disease activity, a high index of suspicion and prompt 
investigation of suspected cardiac disease. 
         
 
 
 
 
 
CONCLUSION 
 
In this cross sectional study on Rheumatoid arthritis, 
 Carotid intima media thickness in RA cases was found to be significantly 
increased when compared  to age and sex matched  healthy controls 
indicating that Rheumatoid arthritis is an independent risk factor for 
accelerated  atherosclerosis  
 Increase in carotid intima media thickness was found to be directly related to 
the duration of the disease. 
 Our study did not show significant relationship between disease activity and 
carotid intima media thickness.  
    So, early diagnosis of evidence of unfavorable vascular profile in RA patients 
and instituting appropriate preventive therapies can decrease the cardiovascular 
mortality due to Rheumatoid arthritis. 
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PROFORMA 
        Name:     Age:  Sex:  O.P. No. : 
 I.P.No.  
       Address: 
 History:    Symptoms:  Morning stiffness 
                                       Joint pain 
                                                  Joint swelling 
                                                  Joints involved 
                            Duration of symptoms: 
         Past history of:   DM       
                                         HTN 
                                         CAD 
                                         CVA 
Personal history:  Smoking 
               Alcohol intake 
Treatment History: 
 
 Examination  
            Pallor                                                                    Clubbing 
            Icterus                                                                  Lymphadenopathy              
            Cyanosis                                                              Pedal edema 
          Vitals: 
               Pulse:                                         BP: 
               RR:                                            Temperature: 
          Rheumatological: 
 Rheumatoid Nodules 
 Joints involved 
 Tender joints count 
 Swollen joints count 
 Deformity 
 Systemic Examination: 
 CVS : 
 RS : 
 PA : 
 CNS : 
Investigations: 
 Hematological  
                    Hb% :                                               TC   :    
                     DC    :                                               ESR  : 
 Biochemical 
                           Blood sugar : 
                           Urea  : 
                           Creatinine : 
                           S.Uricacid : 
                            
                           Lipid profile: Total cholesterol 
                                                  TGL 
                                                  LDL 
                                                 VLDL 
                                                  HDL 
 Chest X-ray: 
 ECG          : 
 Echocardiogram: 
 RF titre: 
 CRP: 
 Anti-CCPantibody: 
 Carotid Intima Media thickness: 
DAS28 score:  
 
MASTER CHART 
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1 52 M N N N N N N 133 44 1.1 182 154 82 37 38 6
2 35 M N N N N N N 92 28 0.9 158 162 98 40 41 5.2
3 60 M N N N N N N 78 32 0.8 180 176 106 36 36 5.5
4 49 M N N N N N N 82 28 0.7 166 150 93 33 39 5.5
5 43 M N N N N N N 74 22 0.8 157 171 88 35 41 4.5
6 38 M N N N N N N 100 29 0.9 149 160 78 37 42 5
7 35 M N N N N N N 68 18 1 170 154 99 31 40 4.9
8 50 M N N N N N N 80 21 1 188 161 123 42 37 6.3
9 43 M N N N N N N 136 33 0.9 155 146 112 37 40 5.5
10 45 M N N N N N N 62 27 1.1 140 139 99 32 38 5.8
11 53 M N N N N N N 94 18 0.9 188 175 78 33 40 6
12 40 M N N N N N N 66 24 0.8 144 138 82 34 42 5.4
13 39 F N N N N N N 78 18 0.9 154 162 98 38 39 5.3
14 46 F N N N N N N 123 33 1 128 138 76 33 40 5
15 37 F N N N N N N 132 44 0.9 160 155 77 35 42 5.8
16 54 F N N N N N N 94 24 0.7 182 160 98 34 38 5.6
17 35 F N N N N N N 75 41 1 166 142 120 38 34 4.8
18 36 F N N N N N N 68 22 0.7 180 153 88 32 41 5.5
19 60 F N N N N N N 70 24 0.9 192 168 112 41 34 6.5
20 57 F N N N N N N 88 38 1.1 168 152 78 38 40 6.4
21 58 F N N N N N N 86 32 0.8 166 158 99 37 36 6
22 41 F N N N N N N 93 28 1 158 146 96 33 41 5.6
23 45 F N N N N N N 84 18 0.9 165 152 88 34 38 5.8
24 36 F N N N N N N 122 24 0.7 182 128 110 40 36 5.3
25 50 F N N N N N N 68 42 0.9 200 176 98 32 40 6
26 45 F N N N N N N 84 22 0.7 166 155 77 38 37 5.9
27 46 F N N N N N N 120 20 1.1 177 160 108 28 42 5.5
28 55 F N N N N N N 132 25 1 158 146 99 29 38 5.7
29 52 F N N N N N N 90 17 0.8 169 149 82 33 43 6.1
30 35 F N N N N N N 76 16 0.9 188 165 90 36 38 5.5
31 45 F N N N N N N 66 43 0.7 202 166 102 40 37 5.8
32 50 F N N N N N N 64 19 1 187 165 86 37 40 5.9
33 28 F N N N N N N 76 22 0.7 154 144 78 35 39 5
34 57 F N N N N N N 75 41 1.1 186 152 113 41 33 6.2
35 48 F N N N N N N 96 32 1 168 149 82 36 40 5.6
36 49 F N N N N N N 78 49 0.9 154 139 77 32 41 6.1
37 29 F N N N N N N 62 18 0.7 144 138 92 27 44 5.3
38 47 F N N N N N N 84 33 1 187 160 77 32 41 5.6
39 20 F N N N N N N 91 22 0.7 166 142 88 31 42 5
40 32 F N N N N N N 128 20 1 156 133 79 34 43 5.9
MASTER CHART - CONTROLS
 
KEY TO MASTER CHART 
 
 DM        -     Diabetes mellitus. 
 HT         -     Hypertension. 
 CAD      -     Coronary artery disease 
 CVA      -     Cerebrovascular accident 
 EMS      -     Early morning stiffness. 
 TJC       -     Tender joint count. 
 SJC       -     Swollen joint count. 
 T.CHL  -     Total cholesterol. 
 TGL      -     Triglycerides. 
 LDL      -     Low density lipoprotein. 
 HDL      -    High density lipoprotein. 
 ESR       -    Erythrocyte sedimentation rate 
 CRP      -     C-reactive protein 
 GH        -     General health on visual analogue scale. 
 DAS28   -     Disease activity score28 
 RF         -     Rheumatoid factor 
 CIMT    -     Carotid intima media thickness 
 P            -      Present 
 N           -       Not present 
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